- Available:In stock875
- Availability date:2020-07-30
- Dosage form:Tablets
- In stock:876 Items
vincamine has a selective vasoregulatory effect on cerebral circulation, helping to adapt cerebral circulation to the metabolic needs of the brain. the drug improves brain metabolism by enhancing glucose oxidation, thereby increasing energy production and contributing to an increase in the overall activity of the body. Vincamine increases the supply of oxygen to neurons in a state of hypoxia. the drug reduces and stabilizes the peripheral resistance of the vessels of the brain. It is proved that vincamine does not have biological, hematological toxicity and side effects on the kidneys and liver.
Pharmacokinetics Quickly absorbed in the digestive tract, T½ - 60–90 min, binding to blood plasma proteins - 64%. Vincamine is completely metabolized in the liver, only 4-6% is excreted unchanged in the urine.
To normalize and adapt cerebral circulation in accordance with the metabolic needs of the brain: to improve, regulate and maintain brain functions in such conditions:
- memory impairment;
- impaired concentration of attention;
- diabetic angiopathy;
- atherosclerotic lesion of cerebral vessels;
- post-traumatic craniocerebral disorders;
- after acute cerebrovascular accident;
- cerebral disorders after cerebral ischemia;
- hypertensive encephalopathy;
- impaired hearing and vision of vascular origin;
- disorientation in space and time, emotional disorders that are consequences of various mental disorders.
Adults are prescribed 1 tablet inside 2 times a day. the duration of treatment is determined by the doctor individually, depending on the course of the disease.
Hypersensitivity to any component of the drug. a brain tumor (or diseases that cause an increase in intracranial pressure), convulsive disorders, acute stroke, heart rhythm disturbance, severe electrolyte disturbances (hypokalemia or hypocalcemia).
Mental disorders: a slight increase in mental activity.
From the nervous system: headache, dizziness.
From the cardiovascular system: lengthening of the Q – T interval, flutter-ventricular fibrillation (torsade des pointes).
From the digestive system: nausea, heartburn, diarrhea, constipation, dry mouth.
From the immune system: hypersensitivity reactions, including angioedema.
From the skin and subcutaneous tissue: erythema, itching, allergic dermatitis, urticaria, papular rashes.
Do not exceed recommended doses. use with caution in patients with myocardial infarction, heart disease, or heart failure. in such cases, low initial doses are used, clinical observation, and ECG monitoring are carried out. Do not use when lengthening the q – t interval, since there is a risk of developing ventricular rhythm disturbances.
With prolonged use of vincamine, liver function should be monitored.
The drug contains lactose, so it should not be prescribed to patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.
Use during pregnancy or lactation. Contraindicated.
Children. Vinoxin MV tablets are not recommended for use in children.
The ability to influence the reaction rate when driving vehicles or working with other mechanisms. Vincamine can affect the reaction rate when driving vehicles or working with other mechanisms.
Avoid co-administration with drugs that may cause torsade des pointes. if this is not possible, careful clinical and ecg monitoring is recommended.
Interactions characteristic of vinca alkaloid.
Quinupristine and dalphopristine are potent inhibitors of cytochrome P450 ZA4 and can increase the concentration of vinca alkaloid when used together. Patients should be monitored to detect adverse symptoms of vinca alkaloid, and accordingly, the dose of vincamine should be adjusted.
A possible mechanism of interaction between itraconazole and vinca alkaloid is the inhibition of cytochrome P450 by itraconazole. Itraconazole can also inhibit the P-glycoprotein pump, responsible for the excretion of vinca alkaloid. Therefore, with the combined use of itraconazole and vincamine, patients should be closely monitored.
In case of overdose, careful clinical observation, ECG monitoring, symptomatic treatment and maintenance of vital body functions are recommended. there is no specific antidote.
In the original packaging at a temperature not exceeding 25 ° C.
Tags: Vinoxin® [Vincamine]